Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jesus Soberino"'
Autor:
Raúl Márquez Vázquez, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Jesus Soberino, Susana de la Cruz Sánchez, Peter Schmid, Aleix Prat, Miguel Angel Seguí-Palmer, María Gión Cortés, Andrea Malfettone, Vicente Carañana, Javier Cortes, Lourdes Calvo, Begoña Bermejo, Manuel Ruiz Borrego, Giuseppe Curigliano, Jose Luis Alonso, Jose Perez-Garcia, Elena López-Miranda
Publikováno v:
European Journal of Cancer. 148:382-394
Background Pembrolizumab has modest activity if used in patients with hormone-receptor–positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77826c81ce42c3ca11452e8188ac513
https://doi.org/10.1016/j.ejca.2021.02.028
https://doi.org/10.1016/j.ejca.2021.02.028
Autor:
José Manuel Pérez-García, Antonio Llombart-Cussac, Esther Holgado, Giuseppe Curigliano, Elena López Miranda, José Luis Alonso-Romero, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Susana de la Cruz Sánchez, María Gión Cortés, Raúl Márquez Vázquez, Aleix Prat, Manuel Ruiz Borrego, Miguel Sampayo, Miguel Àngel Seguí, Jesus Soberino, Andrea Malfettone, Peter Schmid, Javier Cortés
Publikováno v:
Cancer Research. 80:P3-09
BACKGROUND: Studies of checkpoint inhibitor monotherapy have shown only modest activity in hormone receptor (HR)-positive (+)/human epidermal growth factor receptor 2 (HER2)-negative (-) metastatic breast cancer (MBC). However, pembrolizumab (P) adde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e349ff29c5e24cae828097f91532800
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03
Publikováno v:
Current Breast Cancer Reports. 11:248-258
To summarize and discuss the available evidence and ongoing efforts in order to establish the efficacy and safety of immunotherapeutic approaches in HER2-positive breast cancer. The introduction into the clinic of anti-HER2–targeted therapies more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0b17df4760f337e3ecaec7f2a2a932c
https://doi.org/10.1007/s12609-019-00332-4
https://doi.org/10.1007/s12609-019-00332-4
Autor:
Elena López-Miranda, Begoña Bermejo, Fatima Cardoso, M. Gion, Andrea Malfettone, Sofia Braga, M. Martinez Garcia, Jesus Soberino, Miguel Sampayo, A. Llombart Cussac, Jose Perez-Garcia, J. Cortés, Cláudia Vieira
Publikováno v:
Annals of Oncology. 32:S513
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c76e974c979fa6b11d204f45a2cc715e
https://doi.org/10.1016/j.annonc.2021.08.619
https://doi.org/10.1016/j.annonc.2021.08.619
Autor:
Olga Martínez-Sáez, Francesco Schettini, Nuria Chic, D. Martinez, Joaquín Gavilá, Cristina Saura, Charles M. Perou, Patricia Galván, Meritxell Bellet, Eva Ciruelos, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Javier Cortes, T. Pascual, Aleix Prat, Mafalda Oliveira, Jesus Soberino, Sonia Pernas, Maria Vidal, Montserrat Muñoz, Esther Sanfeliu, Fara Brasó-Maristany
Publikováno v:
EBioMedicine, Vol 69, Iss, Pp 103451-(2021)
EBioMedicine
EBioMedicine
Background Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. Methods We compared early-stage HR+ BC biological features before and after (neo)adjuvan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea3c418bd64eba850cd7011f38f8e01
https://doi.org/10.1016/j.ebiom.2021.103451
https://doi.org/10.1016/j.ebiom.2021.103451
Publikováno v:
Her2-Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e81fe220e8b9e1587d02aaad8f878881
https://doi.org/10.1016/b978-0-323-58122-6.00008-8
https://doi.org/10.1016/b978-0-323-58122-6.00008-8
Autor:
L. Gomila, N. Ortega, Vicente Peg, Jesus Soberino, J. Cortes, Jose Manuel Trigo Perez, Isabel T. Rubio, A. Esgueva-Colmenarejo, R. Rodriguez-Revuelto
Publikováno v:
European Journal of Cancer. 92:S13-S14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::672dca10706543e6ce31e2d9ecb3dc93
https://doi.org/10.1016/s0959-8049(18)30280-6
https://doi.org/10.1016/s0959-8049(18)30280-6
Publikováno v:
International Journal of Molecular Sciences
The unconventional secretion of proteins is generally caused by cellular stress. During the tumorigenesis, tumor cells experience high levels of stress, and the secretion of some theoretically intracellular proteins is activated. Once in the extracel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d142517c509ed3c2281f03658bc37ed3
https://doi.org/10.3390/ijms20235950
https://doi.org/10.3390/ijms20235950
Autor:
Cristina Saura, Evandro De Azambuja, Mafalda Oliveira, Peter Christian Dubsky, Dimitrios Zardavas, Christian Fesl, Aditya Bardia, Jesus Soberino, Monica N. Fornier, Katalin Boer, Vivian Ng, Jill O. Fredrickson, Thomas Stout, Stina Singel, Jerry Y. Hsu, Martine J. Piccart-Gebhart, Jose Baselga, Michael Gnant
Publikováno v:
Journal of Clinical Oncology. 34:TPS613-TPS613
TPS613Background: Taselisib is an orally bioavailable, potent, selective inhibitor of Class I PI3-kinase (PI3K) alpha, gamma, and delta isoforms, with 30-fold less inhibition of the PI3K beta isofo...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae902c3ff769f85acc4de63ff3510618
https://doi.org/10.1200/jco.2016.34.15_suppl.tps613
https://doi.org/10.1200/jco.2016.34.15_suppl.tps613
Autor:
Jesus Soberino, Cinta Hierro, Jose Perez-Garcia, Mafalda Oliveira, Rodrigo Dienstmann, V Ortega, Fiorella Ruiz, Maria Vidal, Javier Cortes, Meritxell Bellet, Patricia Gómez-Pardo, Eva Muñoz-Couselo, Cristina Saura, Ana Vivancos, Esther Zamora, Paolo Nuciforo
Publikováno v:
Journal of Clinical Oncology. 34:528-528
528Background: PAMi are being developed in unselected populations with MBC, but not all pts derive equal benefit. Aim: to assess predictive factors influencing PAMi efficacy in MBC pts enrolled in ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::247fe8101e6776534703a212fc8a914d
https://doi.org/10.1200/jco.2016.34.15_suppl.528
https://doi.org/10.1200/jco.2016.34.15_suppl.528